Adjuvant tislelizumab plus TACE in resected high-risk hepatocellular carcinoma (ATTACK): Preliminary analysis of a prospective cohort study

被引：0
作者：
Liu, J. [1 ]
Zeng, D. [2 ]
Cheng, Y. [1 ]
Li, Y. [1 ]
Zhang, M. [1 ]
Song, S. [2 ]
Huang, Y. [1 ]
机构：
[1] Shanghai Publ Hlth Clin Ctr, Hepatobiliary Surg Dept, Shanghai, Peoples R China
[2] Shanghai Publ Hlth Clin Ctr, Dept Pathol, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.247
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
227P
引用
收藏
页码：S1490 / S1490
页数：1
相关论文
共 50 条
[31]   Tislelizumab plus sitravatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgical resection: Preliminary analysis of a multi-center, non-randomized, open-label phase 2 study [J].
Wang, Jiabei ;
Peng, Tao ;
Liu, Chang ;
Zhang, Ling ;
Zhu, Guangzhi ;
Zhang, Xiaogang ;
Wang, Xiaoqian ;
Liu, Lianxin .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[32]   Perioperative lenvatinib combined with tislelizumab plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase 2 trial. [J].
Wu, Jia-Yi ;
Fu, Yang-Kai ;
Wen, Tianfu ;
Wang, Shuang-Jia ;
Chen, Jiafei ;
Zhang, Zhibo ;
Liu, Chongyuan ;
Wang, Wei ;
Fang, Lu ;
Tang, Zhong ;
Chen, Yufeng ;
Yan, Maolin .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) :503-503
[33]   Adjuvant tislelizumab combined with capecitabine for patients with biliary tract cancer with high risk of postoperative relapse (ACTIVE): Primary analysis from a prospective cohort study [J].
Yang, Luyu ;
Lu, Lu ;
Wang, Xiangyu ;
Sun, Haoting ;
Zhu, Ying ;
Xu, Da ;
Yang, Jimeng ;
Yin, Baobing ;
Yang, Xin ;
Zhu, Wenwei ;
Jia, Huliang ;
Chen, Jinhong ;
Qin, Lunxiu .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[34]   Use of Adjuvant Sorafenib in Liver Transplant Recipients with High-Risk Hepatocellular Carcinoma [J].
Shetty, Kirti ;
Dash, Chiranjeev ;
Laurin, Jacqueline .
JOURNAL OF TRANSPLANTATION, 2014, 2014
[35]   The risk of hepatocellular carcinoma associated with blood iron profile: Preliminary findings from a prospective cohort study [J].
Jenab, M. ;
Duarte-Salles, T. ;
Stepien, M. ;
Romieu, I. ;
Bamia, C. ;
Trichopoulou, A. .
EUROPEAN JOURNAL OF CANCER, 2013, 49 :S305-S305
[36]   Efficacy and safety analysis of TACE plus Donafenib plus Toripalimab versus TACE plus Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study [J].
Lu, Haohao ;
Liang, Bin ;
Xia, Xiangwen ;
Zheng, Chuansheng .
BMC CANCER, 2023, 23 (01)
[37]   Efficacy and safety analysis of TACE plus PEI plus lenvatinib compared with TACE plus lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study [J].
Lu, Haohao ;
Zheng, Chuansheng ;
Liang, Bin ;
Xia, Xiangwen ;
Fan, Hongjie .
FRONTIERS IN ONCOLOGY, 2024, 14
[38]   Preliminary report of outpatient weekly adjuvant chemotherapy for high-risk nasopharyngeal carcinoma [J].
Lin, JC ;
Jan, JS ;
Hsu, CY .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (06) :624-627
[39]   Analysis of efficacy and safety for the combination of tislelizumab and regorafenib in advanced hepatocellular carcinoma: A prospective clinical study [J].
Sun, Pengfei ;
Zhang, Ying ;
Tian, Shilin ;
Cui, Kai ;
Zhong, Jingtao ;
Zhang, Chengsheng ;
Wang, Dongxu ;
Zhang, Bo ;
Shi, Xuetao ;
Li, Zhongchao .
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2024, 20 (04) :1344-1349
[40]   Risk factors for the development of hepatocellular carcinoma in Chengdu: a prospective cohort study [J].
Cao, Q. ;
Zhang, Q. ;
Chen, Y. -Q. ;
Fan, A. -D. ;
Zhang, X. -L. .
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (24) :9447-9456
12345